GALECTIN THERAPEUTICS INC. Retained Earnings
GALECTIN THERAPEUTICS INC. (GALT) had Retained Earnings of -$446.79 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$446.79M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$437.61M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$432.55M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$426.98M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$446.79M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$437.61M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$432.55M 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$426.98M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$418.76M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$411.18M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$401.57M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$389.54M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$378.30M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$365.87M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$354.37M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$344.31M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$330.27M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$321.09M 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$309.57M 10-K · filed 2024-03-29 |
| 2022-09-30 | -$298.87M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$290.29M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$280.61M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$270.69M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$263.41M 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$254.85M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$246.34M 10-Q · filed 2021-05-17 |
| 2020-12-31 | -$240.00M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$232.08M 10-Q · filed 2020-11-09 |
| 2020-06-30 | -$226.13M 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$219.94M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$216.39M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$211.19M 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$208.37M 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$205.31M 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$196.22M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$192.87M 10-Q · filed 2018-11-13 |
| 2018-06-30 | -$189.82M 10-Q · filed 2018-08-14 |
| 2018-03-31 | -$185.71M 10-Q · filed 2018-05-11 |
| 2017-12-31 | -$181.17M 10-K · filed 2019-03-06 |
| 2017-09-30 | -$178.38M 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$173.72M 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$168.91M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$163.70M 10-K · filed 2018-03-29 |
| 2016-09-30 | -$158.52M 10-Q · filed 2016-11-08 |
| 2016-06-30 | -$152.89M 10-Q · filed 2016-08-09 |
| 2016-03-31 | -$147.06M 10-Q · filed 2016-05-10 |
| 2015-12-31 | -$140.05M 10-K · filed 2017-03-28 |
| 2015-09-30 | -$135.08M 10-Q · filed 2015-11-09 |
| 2015-06-30 | -$128.93M 10-Q · filed 2015-08-10 |
| 2015-03-31 | -$124.00M 10-Q · filed 2015-05-11 |
| 2014-12-31 | -$118.92M 10-K · filed 2016-03-15 |
| 2014-09-30 | -$114.89M 10-Q · filed 2014-11-10 |
| 2014-06-30 | -$111.10M 10-Q · filed 2014-08-07 |
| 2013-12-31 | -$101.97M 10-K · filed 2015-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |